Literature DB >> 22287157

Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer.

J Segelman1, F Granath, T Holm, M Machado, H Mahteme, A Martling.   

Abstract

BACKGROUND: This was a population-based cohort study to determine the incidence, prevalence and risk factors for peritoneal carcinomatosis (PC) from colorectal cancer.
METHODS: Prospectively collected data were obtained from the Regional Quality Registry. The Cox proportional hazards regression model was used for multivariable analysis of clinicopathological factors to determine independent predictors of PC.
RESULTS: All 11 124 patients with colorectal cancer in Stockholm County during 1995-2007 were included and followed until 2010. In total, 924 patients (8.3 per cent) had synchronous or metachronous PC. PC was the first and only localization of metastases in 535 patients (4.8 per cent). The prevalence of synchronous PC was 4.3 per cent (477 of 11 124). The cumulative incidence of metachronous PC was 4.2 per cent (447 of 10 646). Independent predictors for metachronous PC were colonic cancer (hazard ratio (HR) 1.77, 95 per cent confidence interval 1.31 to 2.39; P = 0.002 for right-sided colonic cancer), advanced tumour (T) status (HR 9.98, 3.10 to 32.11; P < 0.001 for T4), advanced node (N) status (HR 7.41, 4.78 to 11.51; P < 0.001 for N2 with fewer than 12 lymph nodes examined), emergency surgery (HR 2.11, 1.66 to 2.69; P < 0.001) and non-radical resection of the primary tumour (HR 2.75, 2.10 to 3.61; P < 0.001 for R2 resection). Patients aged > 70 years had a decreased risk of metachronous PC (HR 0.69, 0.55 to 0.87; P = 0.003).
CONCLUSION: PC is common in patients with colorectal cancer and is associated with identifiable risk factors.
Copyright © 2012 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22287157     DOI: 10.1002/bjs.8679

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  99 in total

Review 1.  [Prognostic biomarkers for metastatic colorectal cancer].

Authors:  J H L Neumann
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

Review 2.  Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?

Authors:  Camille L Stewart; Susanne Warner; Kaori Ito; Mustafa Raoof; Geena X Wu; Jonathan Kessler; Jae Y Kim; Yuman Fong
Journal:  Curr Probl Surg       Date:  2018-10-04       Impact factor: 1.909

Review 3.  Systemic therapy in addition to cytoreduction and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: recent insights from clinical studies and translational research.

Authors:  Checca Bakkers; Geert A A M Simkens; Ignace H J T De Hingh
Journal:  J Gastrointest Oncol       Date:  2021-04

Review 4.  Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure.

Authors:  Loek A W de Jong; Fortuné M K Elekonawo; Philip R de Reuver; Andre J A Bremers; Johannes H W de Wilt; Frank G A Jansman; Rob Ter Heine; Nielka P van Erp
Journal:  Br J Clin Pharmacol       Date:  2018-10-25       Impact factor: 4.335

5.  Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy?

Authors:  H Ishida; K Kumamoto; K Ishibashi; S Hatano; T Matsuzawa; N Okada; Y Kumagai; H Baba; N Haga
Journal:  Tech Coloproctol       Date:  2013-02-07       Impact factor: 3.781

Review 6.  Current treatment options for colon cancer peritoneal carcinomatosis.

Authors:  Tomoyoshi Aoyagi; Krista P Terracina; Ali Raza; Kazuaki Takabe
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

7.  Benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with isolated peritoneal metastases from colorectal cancer.

Authors:  Pompiliu Piso; Kathrin Stierstorfer; Michael Gerken; Monika Klinkhammer-Schalke
Journal:  Int J Colorectal Dis       Date:  2018-08-21       Impact factor: 2.571

8.  Adjuvant intraperitoneal chemotherapy for the treatment of colorectal cancer at risk for peritoneal carcinomatosis: a systematic review.

Authors:  Paul L Feingold; Nicholas D Klemen; Mei Li M Kwong; Barry Hashimoto; Udo Rudloff
Journal:  Int J Hyperthermia       Date:  2017-12-07       Impact factor: 3.914

9.  Peritoneal carcinomatosis of colorectal cancer is characterized by structural and functional reorganization of the tumor microenvironment inducing senescence and proliferation arrest in cancer cells.

Authors:  Caroline Theresa Seebauer; Stefan Brunner; Gabriel Glockzin; Pompiliu Piso; Petra Ruemmele; Hans-Juergen Schlitt; Edward Kenneth Geissler; Stefan Fichtner-Feigl; Rebecca Kesselring
Journal:  Oncoimmunology       Date:  2016-10-14       Impact factor: 8.110

10.  Leukocytes recruited by tumor-derived HMGB1 sustain peritoneal carcinomatosis.

Authors:  Lucia Cottone; Annalisa Capobianco; Chiara Gualteroni; Antonella Monno; Isabella Raccagni; Silvia Valtorta; Tamara Canu; Tiziano Di Tomaso; Angelo Lombardo; Antonio Esposito; Rosa Maria Moresco; Alessandro Del Maschio; Luigi Naldini; Patrizia Rovere-Querini; Marco E Bianchi; Angelo A Manfredi
Journal:  Oncoimmunology       Date:  2016-01-08       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.